Sofosbuvir Containing Regimens for the Treatment of Chronic HCV GT3 Infected Patients

PHASE3CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 31, 2015

Primary Completion Date

December 31, 2017

Study Completion Date

March 15, 2018

Conditions

Chronic Hepatitis C Infection

Interventions

DRUG

sofosbuvir and daclatasvir

Sofosbuvir (SOF) 400 mg tablet administered orally once daily. Daclatasvir (DCV) 60 mg tablet administered orally once daily.

DRUG

ledipasvir/sofosbuvir

"Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed dose combination (FDC) tablet administered orally.~once daily;"

Trial Locations (2)

Liver Fibrosis Diagnosis and Treatment Centre, 302 Hospital, Beijing

Humanity and Health GI and Liver Centre, Hong Kong

All Listed Sponsors

collaborator

Beijing 302 Hospital

OTHER

lead

Humanity and Health Research Centre

OTHER

NCT02576314 - Sofosbuvir Containing Regimens for the Treatment of Chronic HCV GT3 Infected Patients | Biotech Hunter | Biotech Hunter